Novartis Stock

Novartis EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Novartis (NOVN.SW) as of Aug 8, 2026 is 22.36. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 29.36 — a change of -23.85% (lower).

EV/FCF

22.36

YoY

-23.85%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Novartis is 2026 22.36 . EV/FCF (Enterprise Value to Free Cash Flow) of Novartis was 2025 29.36 . It decreases by -23.85% lower compared to the previous year.
Access this data via the Eulerpool API

Novartis Stock analysis

What does Novartis do? Novartis AG is a globally active company operating in the pharmaceutical, ophthalmology, and generics manufacturing sectors. The company, headquartered in Basel, Switzerland, was founded in 1996 and originated from a merger between Ciba-Geigy and Sandoz. Novartis AG is now a leading company worldwide in the research, development, production, and marketing of pharmaceuticals and other health products. Novartis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Novartis stock

EV/FCF (Enterprise Value to Free Cash Flow) of Novartis is 22.36 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Novartis changed from 29.36 to 22.36, representing a -23.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Novartis since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Novartis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Novartis

All Key Metrics — Novartis